

## STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-134)	ACAPATAMAB
PRONUNCIATION	ak" a pat' a mab
THERAPEUTIC CLAIM	Treatment of prostate cancer
CHEMICAL NAMES	

1. Immunoglobulin, anti-(human prostate-specific membrane antigen) (human monoclonal 76B10scmAbc single-chain variable fragment VH1-(GGGGS)3-VL1) fusion protein with peptide linker (GGGGS) fusion protein with immunoglobulin anti-(human CD3 antigen  $\epsilon$ -chain) (human monoclonal 76B10-scmAbc single-chain variable fragment VH2-(GGGGS)3-VL2) fusion protein with peptide linker (GGGG) fusion protein with immunoglobulin G (human  $\gamma$ -chain C-region C-terminal fragment) fusion protein with peptide linker (GGGGS)6 fusion protein with immunoglobulin G (human  $\gamma$ -chain C-region C-terminal fragment) (Source: CAS)
2. Immunoglobulin scFv-scFv-scFc, anti-[*Homo sapiens* FOLH1 (Glutamate carboxypeptidase 2, folate hydrolase 1, prostate specific membrane antigen, PSMA)] and anti-[*Homo sapiens* CD3E (T-cell surface glycoprotein CD3 epsilon chain, Leu-4)], monoclonal antibody single chain (scFv)2-scFc, bispecific; IG single chain scFv-scFv-scFc, anti FOLH1 and anti-CD3E (1-986) [scFv-VH-V-kappa anti-FOLH1 (1-243) [VH (*Homo sapiens* IGHV3-11\*01 {G<sup>49</sup>>C(44)} (85%) -(IGHD) -IGHJ4\*01 [8.8.14] (26-33.51-58.97-110) (1-121) -15-mer-tris(tetraglycyl-seryl) linker (122-136)-V-KAPPA (*Homo sapiens* IGKV1-16\*01 (79%) -IGKJ2\*01 {Q<sup>120</sup>>C(236)} (91%)) CDR-IMGT [6.3.9] (163-168.186-188.225-233) (137-243)] -6-mer seryl-tetraglycyl-seryl linker (244-249) -scFv-VH-V-lambda anti-CD3E (250-498) [VH (*Mus musculus* IGHV10-1\*02 (92%) -(IGHD) -IGHJ3\*01 (87%)/*Homo sapiens* IGHV3-73\*01 (87%) -(IGHD) -IGHJ5\*01) CDR-IMGT [8.10.16] (275-282.300-309.348-363) (250-374) -15-mer-tris(tetraglycyl-seryl) linker (375-389) -V-LAMBDA (*Homo sapiens* IGLV7-43\*01 (85%) -IGLJ3\*02) CDR-IMGT [9.3.9] (415-423.441-443.480-488) (390-498)] -4-mer-tetraglycyl linker (499-502) -scFc (h-CH2-CH3)-(h-CH2-CH3) (503-986) [*Homo sapiens* IGHG1\*03 h-CH2-CH3, nG1m1 (hinge 6-15 (503-512), CH2 {R<sup>62</sup>>C(574), N<sup>67</sup>>G(579), V<sup>72</sup>>C(584)} (513-622), CH3 E12 (638), M14 (640) (623-727), CHS (728-729) (503-729) -30-mer hexakis(tetraglycyl-seryl) linker (730-759) -*Homo sapiens* IGHG1\*03 h-CH2-CH3, nG1m1 (hinge 6-15 (760-769), {CH2 R<sup>62</sup>>C(831), N<sup>67</sup>>G(836), V<sup>72</sup>>C(841)} (770-879), CH3 E12 (895), M14 (897) (880-984), CHS (985-986) (760-986)]], non-glycosylated, produced in Chinese hamster ovary (CHO) cells Post-translational modification: K(986) deleted (Source: USAN Program Chemical Consultant)

# STRUCTURAL FORMULA

## Sequence

QVQLVESG	GGG	LVKPGESLRL	SCAASGFTFS	DYYMYWVRQA	PGKCLEWVAI	50
ISDGGYYTY	Y	SDIIKGRFTI	SRDNAKNSLY	LQMNSLKAED	TAVYYCARGF	100
PLLRHGAMDY		WGQGLVTVS	SGGGSGGGG	SGGGGSDIQM	TQSPSSLSAS	150
VGDRVITICK		ASQNVDTNVA	WYQQKPGQAP	KSLIYSASYV	YWDVPSRFSG	200
SASGTDFTLT		ISSVQSEDF	TYQCQQYDQQ	LITFGCGTKL	EIKSGGGGSE	250
VQLVESGGGL		VQPGGSLKLS	CAASGFTFNK	YAMNWVRQAP	GKGLEWVARI	300
RSKYNNYATY		YADSVKDRFT	ISRDDSKNTA	YLQMNNLKTE	DTAVYYCVRH	350
GNFGNSYISY		WAYWGQGLV	TVSSGGGGSG	GGGSGGGGSQ	TVVTQEPSLT	400
VSPGGTFTLT		CGSSTGAVTS	GNYPNWVQK	PGQAPRGLIG	GTKFLAPGTP	450
ARFSGSLLGG		KAALTLSGVQ	PEDEAEYYCV	LWYSNRWVFG	GGTKLTVLGG	500
GGDKTHTCPP		CPAPELLGGP	SVFLFPPKPK	DTLMISRTPE	VTQVVDVSH	550
EDPEVKFNWY		VDGVEVHNAK	TKPCEEQYGS	TYRCVSVLTV	LHQDWLNGKE	600
YKCKVSNKAL		PAPIEKTISK	AKGQPREPQV	YTLPPSREEM	TKNQVSLTCL	650
VKGFYPSDIA		VEWESNGQPE	NNYKTTPPVL	DSDGSFFLYS	KLTVDKSRWQ	700
QGNVFSQVSM		HEALHNHYTQ	KSLSLSPGKG	GGGSGGGGSG	GGGSGGGGSG	750
GGGSGGGGSD		KTHTCPPCPA	PELLGGPSVF	LFPPKPKDTL	MISRTPEVTC	800
VVVDVSHEDP		EVKFNWYVDG	VEVHNAKTKP	CEEQYGSTYR	CVSVLTVLHQ	850
DWLNGKEYKC		KVSNKALPAP	IEKTISKAKG	QPREPQVYTL	PPSREEMTKN	900
QVSLTCLVKG		FYPSDIAVEW	ESNGQPENNY	KTTPPVLDSD	GSFFLYSKLT	950
VDKSRWQQGN		VFSCSVMHEA	LHNHYTQKSL	SLSPGK		986

## Disulfide bridges location

22-96	44-236	159-224	271-347	411-479	508-765
511-768	543-603	574-584	649-707	800-860	906-964 831-841

## No glycosylation site

2 IGHG1 CH2-N67>G(579) & G(836)

## MOLECULAR FORMULA

C<sub>4691</sub>H<sub>7162</sub>N<sub>1262</sub>O<sub>1462</sub>S<sub>38</sub>

## MOLECULAR WEIGHT

105.85 kDa

## TRADEMARK

None as yet

## SPONSOR

Amgen Inc.

## CODE DESIGNATIONS

AMG 160

## CAS REGISTRY NUMBER

2314491-93-3

## UNII

GW5EID3IDO

## WHO NUMBER

11421

gbk